UK-based connected healthcare specialist Wellbeing Software has revealed that it has entered into a partnership with Imbio, a US-based artificial intelligence (AI) provider.
Imbio has developed algorithms which seek to enable clinicians to analyse lung density and texture, turning standard chest CT scans into a map of lung textures. Theoretically, this makes it easier to spot interstitial lung disease (ILD) and other fribrotic conditions.
Through the partnership, the firms aim to provide NHS organisations with the ability to utilise AI in the diagnosis of chronic lung and thoracic conditions.
Wellbeing Software CEO Graham Ridgway said: “We’re committed to giving NHS organisations the best choice when it comes to the adoption of AI and are pleased to welcome Imbio and its pioneering algorithms to the AI Connect Programme and our newly launched AI Market Place, which highlights the different applications of AI we are making available.”
“Algorithms, such as those created by Imbio, have the ability to drastically improve clinical workloads and patient care, but this only becomes a reality when the technology is matched with existing workflows and practices. By enabling this we hope to make the roll-out of AI as simple as possible.”
Imbio COO David Hannes said that his company’s products enable “clinicians to see hidden information in the images and drive data-based, personalised patient care decisions from diagnosis, to therapy tracking, to planning for procedures.”